Expression of the PTEN tumor suppressor is frequently lost in breast cancer in the absence of mutation or promoter methylation through as yet undetermined mechanisms. In this study, we demonstrate that the Rak tyrosine kinase physically interacts with PTEN and phosphorylates PTEN on Tyr336. Knockdown of Rak enhanced the binding of PTEN to its E3 ligase NEDD4-1 and promoted PTEN polyubiquitination, leading to PTEN protein degradation. Notably, ectopic expression of Rak effectively suppressed breast cancer cell proliferation, invasion, and colony formation in vitro and tumor growth in vivo. Furthermore, Rak knockdown was sufficient to transform normal mammary epithelial cells. Therefore, Rak acts as a bona fide tumor suppressor gene through the mechanism of regulating PTEN protein stability and function.
INTRODUCTION
The PTEN (phosphatase and tensin homolog deleted from chromosome 10) tumor suppressor gene, located at chromosome 10q23, is frequently mutated in a number of tumor lineages, including glioblastoma, melanoma, and carcinomas of the prostate, breast, and endometrium Li and Sun, 1997; Steck et al., 1997) . PTEN antagonizes the actions of phosphatidylinositol 3-kinase by dephosphorylating the second messenger phosphatidylinositol 3,4,5-trisphosphate (Cantley and Neel, 1999; Di Cristofano and Pandolfi, 2000; Maehama et al., 2001; Wishart and Dixon, 2002) , regulating activation of the kinase Akt as well as the downstream cellular survival and growth responses (Bellacosa et al., 1991; Chang et al., 1997; Jimenez et al., 1998; Staal, 1987) . PTEN has phosphatase, C2, and PDZ binding domains as well as potential sites of regulation by phosphorylation, including tyrosine phosphorylation, which may contribute to its ability to modulate cell growth and viability.
Emerging evidence shows that complete or partial loss of PTEN protein expression, in addition to gene deletion or mutation, can impact tumor suppression (Salmena et al., 2008) . Indeed, PTEN protein levels are reduced in at least 50% of breast cancers, though gene mutations are rare (Hennessy et al., 2005; Brugge et al., 2007; Stemke-Hale et al., 2008) . The epigenetic regulation of PTEN expression has been attributed to transcriptional regulation, microRNA, and/or alteration of PTEN protein stability (Salmena et al., 2008) . The disruption of PTEN protein stability represents a particularly attractive yet elusive mechanism contributing to its loss in human cancer. Numerous reports have suggested that PTEN stability is regulated by interaction with other proteins and that it is subject to posttranslational modification, particularly phosphorylation (Salmena et al., 2008) . To better understand the regulation of PTEN phosphorylation, stability, and function, we used a proteomics-based approach to systematically identify PTEN-binding proteins.
Rak is a 54 kDa tyrosine kinase that belongs to the Src family of kinases (Anneré n et al., 2003; Cance et al., 1994 ; Serfas and SIGNIFICANCE PTEN protein is frequently absent in cancer, particularly breast cancer, despite a lack of gene mutation. The mechanism causing PTEN protein loss has not been defined. Here we demonstrate that the Rak tyrosine kinase phosphorylates PTEN, protecting it from ubiquitin-mediated degradation. Surprisingly, Rak exhibits strong tumor-suppressive activity in vitro and in vivo, at least in part through regulating PTEN protein stability. Thus, Rak may function as a tumor suppressor gene, and further understanding of its function may contribute to effective therapeutic approaches for both Rak-and PTENdefective cancers. Tyner, 2003) . Like all members of the Src kinase family, the Rak kinase possesses an SH domain as well as conserved autoregulatory tyrosine residues in its catalytic domain (Anneré n et al., 2003; Cance et al., 1994; Serfas and Tyner, 2003) . However, Rak differs significantly from the other Src family members in many structural features, including the presence of a putative bipartite nuclear localization signal and the lack of a consensus myristoylation motif (Anneré n et al., 2003; Serfas and Tyner, 2003) . In fact, Rak has been shown to be a nuclear protein with growth-inhibitory effects when ectopically expressed in breast cancer cells (Meyer et al., 2003) . Notably, the Rak gene is located on chromosome 6q21-23, a region that undergoes loss of heterozygosity in 30% of breast cancer cases (Sheng et al., 1996) . However, the mechanisms by which Rak and its substrates function in cancer have remained unexplored. In this study, we demonstrate the functional interaction between Rak and PTEN and provide mechanistic evidence that Rak functions as a bona fide breast tumor suppressor gene.
RESULTS

Rak Is a PTEN-Interacting Protein
To systematically identify proteins involved in regulation of PTEN phosphorylation and/or protein turnover, we carried out immunoaffinity purification followed by mass spectrometry. We demonstrated that the Rak tyrosine kinase represents one of the major PTEN-associated proteins ( Figure 1A ). To validate the mass spectrometry result, we performed immunoprecipitation/western blot analysis and found that PTEN coprecipitated with Rak ( Figure 1B, left) . Reciprocally, Rak could also be pulled down when an antibody against PTEN was used for immunoprecipitation (Figure 1B, right) . This result strongly suggests that endogenous PTEN and Rak physically interact.
To map the binding domain on Rak, we expressed FLAG-tagged wild-type Rak and Rak mutants lacking an SH2 domain (Rak-DSH2) or an SH3 domain (Rak-DSH3) in U2OS cells. We found that PTEN coprecipitated with wild-type Rak and Rak-DSH2, but PTEN binding to Rak-DSH3 was much reduced ( Figure 1C ). We also created three PTEN mutants, PTEN D1-185, PTEN D185-352, and PTEN D353-403. As shown in Figure 1D , Rak coprecipitated with wild-type PTEN and PTEN D353-403, and weakly with PTEN D1-185. However, Rak did not bind to PTEN D185-352. These results provide evidence that the binding of Rak and PTEN is mediated through the interaction between the SH3 domain of Rak and the C2 domain (and perhaps the phosphatase domain as well) of PTEN.
Previous studies have implicated both Rak and PTEN in breast cancer. We therefore further evaluated the correlation between Rak and PTEN protein expression in breast cancer tissues by linear correlation analysis. Among the 42 cases analyzed, Rak expression showed a strong positive correlation with that of PTEN (32 cases, 76.19%) (R 2 = 0.8039, p < 0.01) ( Figure 1E ). High expression of Rak but low expression of PTEN was detected in 7 cases (16.67%), possibly due to PTEN deletion or mutation in breast cancer. There were only 3 cases that showed low expression of Rak but high expression of PTEN ( Figure 1E ). These data suggest a potential link between expression of PTEN and Rak in breast cancer cells.
Rak Regulates PTEN Protein Stability
Next, we sought to determine whether there is a causal relationship between Rak status and PTEN protein levels. To this end, we established two Rak-overexpressing MCF7 breast cancer cell lines (Rak 44 and Rak 45; Figure 1F , left) and three stable Rak-knockdown nontumorigenic MCF10A cell lines (Rak KD1, Rak KD2, and Rak KD3; Figure 1F , right). Interestingly, we found that Rak positively regulated PTEN protein expression without affecting PTEN mRNA levels ( Figure 1G ). PTEN protein expression was significantly increased in the Rak-overexpressing MCF7 cells and was abolished in the Rak-knockdown MCF10A cells.
We further tested whether PTEN activity and levels of its downstream targets were also affected by enforced changes in Rak levels. As shown in the top left panel of Figure 1H , the lipid phosphatase activity of PTEN was increased by 60% when Rak was ectopically expressed in MCF7 cells, suggesting that Rak enhances the capacity of PTEN to dephosphorylate phosphatidylinositol. Consistently, Rak overexpression increased the inhibitory effects of PTEN on downstream targets in the PI3K pathway. We found that overexpression of Rak reduced Akt phosphorylation ( Figure 1H , top right) and repressed b-catenin nuclear localization and activity as indicated by reporter constructs containing three repeats of wild-type (TOP) or mutant (FOP) Tcf4 (T cell factor)-binding sites ( Figure 1H , bottom). PTEN has previously been shown to inhibit nuclear b-catenin accumulation as well as b-catenin transactivation activity (Persad et al., 2001 ). Thus, these data indicate that enforced Rak expression increases PTEN activity, reducing Akt phosphorylation and blocking its downstream signaling. It is worthwhile to note that the MCF7 cells used in our study express the wild-type Akt and therefore are very suitable for the purpose of this study.
Since Rak binds to PTEN and positively regulates PTEN protein expression, we suspected that Rak might regulate PTEN protein stability. To test this possibility, we compared PTEN protein turnover between control and Rak-knockdown cells in the presence of cycloheximide (CHX), which blocks protein synthesis. As shown in Figure 1I , Rak knockdown led to a reduction in the half-life of PTEN protein from more than 24 hr to less than 6 hr, indicating an essential role of Rak in the stabilization of PTEN protein. Overexpression of Rak also increased the half-life of PTEN in other cell lines, such as the U2OS cells used above (see Figure S1A available online).
PTEN Ubiquitination Is Accelerated in the Absence of Rak
To determine whether Rak regulates PTEN protein stability through the proteasomal pathway, we treated control and Rak-knockdown cells with a 10 mM concentration of the proteasome inhibitor MG132. MG132 treatment substantially increased PTEN protein levels in Rak-knockdown cells but only slightly increased PTEN expression levels in control cells (Figure 2A ), indicating that Rak protects PTEN from proteasome-dependent degradation.
It has recently been reported that PTEN protein levels are regulated in part by proteasomal degradation through the ubiquitin ligase NEDD4-1 (Wang et al., 2007) . To investigate whether Rak regulates PTEN ubiquitination, we performed an in vivo ubiquitination assay. First, MCF7 cells were cotransfected with Figure 2B , lane 5). Consistently, we also found that PTEN polyubiquitination was increased in the absence of Rak in MCF10A cells and that the treatment of cells with the proteasome inhibitor MG132 caused a robust increase of polyubiquitinated PTEN protein ( Figure 2C) .
In support of a role for Rak in PTEN polyubiquitination, we demonstrated that Rak altered the binding of PTEN with its E3 ligase NEDD4-1. As shown in Figure 2D , Rak knockdown in MCF10A cells resulted in a substantial increase in the association between endogenous PTEN and NEDD4-1 as indicated by coimmunoprecipitation. Furthermore, PTEN polyubiquitination was significantly decreased in the absence of NEDD4-1 ( Figure 2E , lane 2 versus lane 6). Together, our findings strongly indicate that >Rak stabilizes PTEN protein through blocking ubiquitin-mediated proteasomal degradation, likely through reducing PTEN binding to NEDD4-1.
Rak Phosphorylates PTEN on Tyr336
In light of our finding that PTEN is a binding partner of Rak, we investigated whether PTEN is a Rak substrate. In an in vitro kinase assay, Rak could indeed induce PTEN phosphorylation ( Figure 3A) . Consistently, using a phosphotyrosine antibody, we confirmed the phosphorylation of endogenous PTEN in MCF7 cells stably overexpressing Rak ( Figure 3B) . Interestingly, when we tested several PTEN mutants in which tyrosine residues that could play a role in the interaction of PTEN with the membrane were mutated, we found that mutation of Tyr336 abolished the phosphorylation of PTEN by Rak. Furthermore, a kinase-dead Rak mutant (K262R) was unable to phosphorylate PTEN ( Figure 3C ), suggesting that Rak may directly phosphorylate PTEN in intact cells.
Phosphorylation of Tyr336 by Rak Is Required for Maintenance of PTEN Protein Stability
Our studies indicated that Tyr336 of PTEN is required for PTEN phosphorylation by Rak. To explore the functional significance of this phosphorylation, we ectopically expressed either wildtype or Y336F mutant PTEN in cells and measured protein half-lives. As shown in Figure 3D , Y336F mutant PTEN was present at a moderately lower level than wild-type PTEN. Additionally, when cells were treated with CHX, Y336F mutant PTEN had a half-life of less than 4 hr, compared to greater than 24 hr for wild-type PTEN ( Figure 3D ). Furthermore, Y336F mutant PTEN levels were markedly increased by treatment with the proteasome inhibitor MG132 ( Figure 3E ). Consistent with the lack of phosphorylation by Rak, the association between Y336F mutant PTEN and its E3 ligase NEDD4-1 was significantly increased ( Figure 3F ).
To determine whether phosphorylation of Y336 by Rak is functionally important, we compared the phosphatase activity and the growth-inhibitory effect of ectopically expressed wild-type and Y336F mutant PTEN on PTEN-deleted MDA-MB-468 breast cancer cells (mutant PTEN) with or without knockdown of the endogenous Rak gene. As shown in the top panel of Figure 3G , we successfully generated two stable Rak-knockdown MDA-MB-468 clones, Rak KD1 and Rak KD3. We then stably expressed either wild-type or Y336F mutant PTEN in the individual Rak KD1 and Rak KD3 MDA-MB-468 clones. As shown in the bottom panel of Figure 3G , the protein level of the Y336F mutant was lower than that of wild-type PTEN in control MDA-MB-468 cells. The lower level of the Y336F mutant was due to its reduced protein stability, which could be rescued by adding the proteasome inhibitor MG132 ( Figure S2 ). Moreover, knockdown of Rak resulted in decreased levels of wild-type PTEN protein without detectable effects on the level of Y336F mutant PTEN, supporting a critical role of Rak in stabilizing PTEN through phosphorylation of Tyr336. Also, as expected, cells expressing Y336F mutant PTEN exhibited significantly lower phosphatase activity compared to cells expressing wildtype PTEN ( Figure 3H ). Together, these data indicate that phosphorylation of PTEN on Tyr336 by Rak is required for optimal protein stability. In control MDA-MB-468 cells, ectopic expression of wild-type PTEN significantly inhibited cell proliferation. In contrast, the Y336F mutant exerted a less growth-inhibitory effect consistent with its low level of expression. Strikingly, the growth-inhibitory effect of wild-type PTEN was reversed when Rak was knocked down in the cells ( Figure 3I ). Together, these results suggest Figure 4A ). Moreover, overexpression of Rak repressed proliferation ( Figure 4B ) and growth in soft agar of MCF7 cells ( Figure 4C ) as well as other cell lines, such as the U2OS cells used above ( Figures S1B and S1C ). Rak overexpression also suppressed tumor cell invasion in a Matrigel invasion assay that mimics the extracellular matrix in vivo ( Figure 4D ). Given that Rak effectively suppressed phenotypes associated with in vitro transformation, we investigated the effect of Rak expression in a xenograft mouse model. Mice were injected in the mammary glands with Rak-overexpressing MCF7 cells or vector control MCF7 cells and monitored weekly for tumor formation. By week 8, all ten of the mice injected with Rak-overexpressing clones remained tumor free, whereas all five of the control mice had developed tumors (Table 1; Figure 4E ).
Rak Knockdown Transforms Normal Mammary Epithelial Cells
As shown above, Rak overexpression suppressed invasion and proliferation of breast cancer cells both in vitro and in vivo. To further assess whether Rak is a bona fide breast tumor suppressor gene, we sought to determine whether loss of Rak expression would transform normal mammary epithelial cells.
Transformation activity in vitro and tumorigenicity in vivo were evaluated using the three Rak-knockdown MCF10A cell lines described above. Rak knockdown promoted cell proliferation ( Figure 5A ), anchorage-independent growth ( Figure 5B) , and in vitro invasive potential ( Figure 5C ). Notably, when Rak was depleted in MDA-MB-468 (PTEN mutant) cells, its effects on proliferation and anchorage-independent growth were less evident ( Figure 3I ; Figure S3 ), suggesting that PTEN is one of the major targets mediating Rak suppression of cell transformation.
We also investigated whether Rak knockdown in MCF10A cells would allow tumor formation in xenografts. We injected control cells or individual Rak-knockdown clones into mammary glands of nude mice and monitored tumor growth. Notably, all of the mice injected with Rak-knockdown cells, but none of the mice injected with control vector-expressing cells, developed tumors within 3 weeks after injection (Table 2; Figure 5D ). Pathologic analysis of the tumors revealed micropapillary hyperplasia in Rak-knockdown clones ( Figure 5E ). These results demonstrate that loss of Rak is sufficient to induce tumorigenicity in immortalized normal mammary epithelial cells, supporting a role for Rak as a bona fide tumor suppressor in breast cancer.
DISCUSSION
Previous studies have demonstrated that tumor-associated PTEN mutations frequently lead to loss of PTEN protein, with at least 20% of the cases demonstrating high mRNA levels indicative of rapid degradation of mutant PTEN protein in cells (Georgescu et al., 1999) . In fact, PTEN tyrosine mutants, with an associated loss of PTEN protein and tumor suppressor activity, have been detected in many types of cancer. However, little is known about the mechanisms that regulate PTEN protein stability and whether the molecules regulating PTEN stability also function as tumor suppressor genes in human cancer. In this study, we found that expression of Rak, a PTEN-interacting protein, strongly correlates with PTEN protein levels in breast cancer tissues, and we demonstrated that Rak positively regulates PTEN protein stability through phosphorylation of PTEN on Tyr336, which in turn prevents PTEN from ubiquitination and degradation.
Recent studies have shown that PTEN protein stability is regulated by ubiquitin-mediated proteasomal degradation through the E3 ligase NEDD4-1. As with PTEN stability, the mechanisms regulating NEDD4-1 and PTEN association have not been fully elucidated. Since Rak enhances PTEN stability, we suspected that phosphorylation of NEDD4-1 or PTEN by Rak might disrupt the interaction between these two molecules and in turn stabilize PTEN protein. In our studies, we found that Rak efficiently phosphorylates PTEN on Tyr336 but has no detectable kinase activity toward NEDD4-1 (data not shown). Notably, Rak depletion increased the interaction between NEDD4-1 and PTEN, suggesting that phosphorylation of PTEN by Rak may inhibit PTEN binding to NEDD4-1 and subsequent PTEN degradation. Indeed, negative regulation of the binding between E3 ligase and substrate as a consequence of tyrosine phosphorylation has previously been reported. For example, Fyn has been shown to phosphorylate the E3 ubiquitin ligase Itch and to reduce its binding to and degradation of its substrate JunB (Yang et al., 2006) . Notably, Fyn and Rak belong to the same kinase family, and Itch is a HECT-type E3 ligase, like NEDD4-1. Thus, the regulatory mechanisms are similar, except that Rak phosphorylates the substrate whereas Fyn phosphorylates the E3 ligase. It is tempting to speculate that tyrosine phosphorylation may be a common mechanism for regulation of protein stability, in which tyrosine kinases protect substrates from HECT-mediated degradation. This mechanism is in contrast to the one by which serine/ threonine kinases promote F box-containing E3 ligase-mediated ubiquitination and protein degradation.
In addition to elucidating a mechanism that regulates PTEN protein stability, as illustrated in Figure 6 , our studies also identified Rak as having the potential to act as a tumor suppressor gene in breast cancer. Rak is located a region that undergoes loss of heterozygosity in 30% of breast cancer cases. However, the role of Rak in breast cancer development is far from clear. Although we identified PTEN as an important substrate for Rak and one that may play crucial role in Rak's tumor suppressor function, we cannot rule out the possibility that Rak may also suppress tumor growth through one or more PTEN-independent bovine pituitary extract. Cells were incubated at 37 C in a humidified incubator with 5% CO 2 .
The pCMV5-3 3 FLAG vector encoding Rak was provided by F.M.-B. The K262R point mutation was created from 3 3 FLAG-Rak using the GeneTailor Site-Directed Mutagenesis System (Invitrogen). The Rak deletion mutants Rak-DSH2 and Rak-DSH3 (Meyer et al., 2003) were provided by R.J.C. pCMV5-3 3 FLAG and pCMV5-3 3 FLAG-PTEN, -PTEN PTEN deletion mutants were generated by PCR (see Figure 1D ). His-PTEN (883 pET15b PTEN) was purchased from Addgene. Full-length NEDD4-1 cDNA was amplified by polymerase chain reaction and subcloned into pGEX-5T-3 (Amersham Pharmacia Biotech). The identity of all plasmids was confirmed by sequencing at the M.D. Anderson Cancer Center DNA Core Sequencing Facility.
Antibodies and Reagents
Nucleotides 448-1433 were subcloned into pGEX-4T with the sense primer 5 0 -TTTTGGATCCATGAGCAACATcTGTCAGAGG-3 0 and the antisense primer 5 0 -TTTTCTCGAGTTTCACTGCTACTGGAGTGGT-3 0 , and the protein product was used for immunization for rabbit polyclonal anti-Rak antibody (Proteintech Group, Inc.). Anti-PTEN antibody was purchased from Cell Signaling Technology. Anti-FLAG M2 and anti-b-actin were purchased from Sigma. Cycloheximide was obtained from Sigma and used at 10 mg/ml (MCF10A cells) or 40 mg/ml (U2OS cells); MG132 (carbobenzoxy-L-leucyl-L-leucyl-L-leucine) was obtained from EMD Biosciences and used at 10 mM.
Affinity Purification of PTEN Protein Complex U2OS cells were transiently transfected with empty vector or FLAG-PTEN plasmids. Forty-eight hours later, whole cellular extracts were prepared with RIPA buffer (50 mM Tris-HCl [pH 7.4], 1% NP40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM sodium orthovanadate, and 1 mM NaF) and immunoprecipitated with anti-FLAG M2 affinity gel (Sigma) overnight. Bead-bound immunocomplexes were eluted with 3 3 FLAG peptide and subjected to SDS-PAGE. Silver staining was performed with a SilverSNAP mass spectrometry kit (Pierce). Specific bands were excised and digested, and the peptides were analyzed by mass spectrometry analysis at the M.D. Anderson Cancer Center Proteomics Facility.
Preparation of Recombinant Proteins
The plasmids pGEX-5T-3-Rak and -NEDD4-1 were used to express recombinant GST-Rak and NEDD4-1 in E. coli strain BL21 (DE3). The GST fusion proteins were expressed by induction overnight at 25 C with 0.1 mM , and -PTEN Y336F were transfected into 293T cells, and fusion proteins were purified using a FLAG fusion protein immunoprecipitation kit (Sigma).
Reverse Transcriptase-Polymerase Chain Reaction cDNA was transcribed using SuperScript III (Invitrogen) following the manufacturer's instructions. Rak was amplified by polymerase chain reaction using the primers 5 0 -ATGAGCAACATCTGTCAGA-3 0 and 5 0 -TCATCTTATGAAGTTATT TGC-3 0 . For amplification of PTEN, the primers 5-GGACGAACTGGTGTAATG ATATG-3 0 and 5-TCTACTGTTTTTGTGAAGTACAGC-3 0 were used.
RNA Interference
Rak knockdown was achieved by RNA interference using a lentiviral vector-based MISSION shRNA (Sigma). Lentiviral particles corresponding to the MISSION shRNA Rak-U22322 target set were used, as well as the MISSION nontarget shRNA control. Specificity and efficacy of the shRNA Rak procedure were controlled by western blotting after transduction and puromycin selection in MCF10A cells. shRNA against NEDD4-1 was purchased from Open Biosystems.
Immunoblotting and Immunoprecipitation
Cells were washed in PBS, and cellular proteins were extracted in modified RIPA buffer (50 mM Tris-HCl [pH 7.4], 1% NP40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM sodium orthovanadate, and 1 mM NaF) for 30 min at 4 C. Lysates were cleared by centrifugation, and proteins were separated by gel electrophoresis. Membranes were blocked in Tris-buffered saline-0.1% Tween 20 (TBS-T)/5% (w/v) milk for 1 hr at room temperature. Membranes were then incubated with primary antibodies diluted in TBS-T/5% (w/v) milk for 2 hr at room temperature. Subsequently, membranes were washed with TBS-T and incubated with horseradish peroxidase secondary antibody (1:4000) (Jackson ImmunoResearch) diluted in TBS-T/5% skim milk. Membranes were washed in TBS-T, and bound antibody was detected by enhanced chemiluminescence (ECL; GE Healthcare). Immunoprecipitation was performed by incubating lysates from 5 3 10 6 cells with 1 mg of antibody at 4 C overnight, followed by addition of 30 ml of protein A/G-conjugated agarose beads (Santa Cruz Biotechnology). The precipitates were washed four times with ice-cold PBS, resuspended in 63 Laemmli buffer, and resolved by SDS-PAGE followed by immunoblotting.
PTEN Lipid Phosphatase Assay
Cells were lysed in 50 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Triton X-100 with protease inhibitors. PTEN was immunoprecipitated by rabbit anti-PTEN antibody. The immunoprecipitates were washed and incubated with water-soluble diC8-phosphatidylinositol 3,4,5-trisphosphate (Echelon Research Laboratories) in 100 mM Tris-HCl (pH 8.0), 10 mM DTT at 37 C for 40 min. The supernatant was collected after the reaction and incubated with Biomol Green Reagent (Biomol) at room temperature for 30 min. PTEN activity was measured by colorimetric detection at OD 650 of the release of phosphate.
In Vitro Proliferation Assay Cells were assayed for MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma) reduction, a measure of mitochondrial viability. In brief, cells were harvested from exponential-phase cultures growing in culture medium, counted, and plated in 96-well flat-bottomed microtiter plates (200 ml cell suspensions, 1 3 10 4 cells/ml). Seventy-two hours later, cells were incubated with MTT substrate (20 mg/ml) for 4 hr, the culture medium was removed, and DMSO was added. The optical density was measured spectrophotometrically at 550 nm. Each experiment was repeated at least three times.
Soft Agar Assay
Cells were resuspended in DMEM containing 0.5% low-melting agarose (Sigma, type VII) and 10% FBS and seeded onto a coating of 1% low-melting agarose in DMEM containing 10% FBS. Colonies were scored 3 weeks after preparation. Colonies larger than 0.1 mm in diameter were scored as positive.
Invasion Assay
Invasion assays were carried out using a cell invasion assay kit (Chemicon) according to the manufacturer's instructions. Briefly, the assay was performed in an invasion chamber consisting of a 24-well tissue culture plate with 12 cell culture inserts. A cell suspension in serum-free culture medium was added to the inserts, and each insert was placed in the lower chamber containing 10% FBS culture medium. After 72 hr incubation in a cell culture incubator, invasiveness was evaluated by staining of cells that had migrated through the extracellular matrix layer and clung to the polycarbonate membrane at the bottom of the insert.
Tumor Growth in Nude Mice
Six-week-old female nude mice were used for experiments. All animal studies were conducted in compliance with animal protocols approved by the M.D. Anderson Cancer Center Institutional Animal Care and Use Committee. Before injection of estrogen receptor-positive MCF7 cells (but not MCF10A), mice were implanted subcutaneously with 0.72 mg 17-b-estradiol 60-day release pellet (E 2 pellet; Innovative Research of America). Mice were injected in the mammary glands with 5 3 10 6 cells from various cell lines in 100 ml PBS. After 1 week, tumors were measured every 2 days. Each cell line was tested in five different animals. For immunohistochemistry, tumor tissue samples were fixed in 10% buffered formalin and processed for histopathologic evaluation by paraffin embedding and hematoxylin and eosin staining.
Transfection and In Vivo Ubiquitination Assay
Cell culture transfection was performed using Lipofectamine 2000 (Invitrogen). For in vivo PTEN ubiquitination assay, transfection was performed when MCF7 cells in 10 cm plates reached 90% confluence. Plasmids encoding PTEN, Rak, and HA-tagged ubiquitin were used in transfections in individual experiments. Forty-eight hours after transfection, cells were harvested, washed with PBS, pelleted, and lysed in RIPA buffer. The cell lysates were then subjected to affinity purification with Ni 2+ resin (Amersham Pharmacia Biotech)
to precipitate His-tagged PTEN with the resin. These precipitated PTEN proteins were separated by SDS-PAGE and detected by immunoblotting with anti-HA antibody. Rak phosphorylates PTEN on Tyr336, which reduces PTEN binding to the E3 ligase NEDD4-1 and subsequent PTEN degradation.
In Vitro Kinase Assay Kinase reactions were performed by mixing purified His-PTEN with or without purified Rak in kinase assay buffer containing 10 mCi [g-32 P]ATP, 10 mM TrisHCl (pH 7.4), 10 mM MgCl 2 , 1.2 mM MnCl 2 , 2 mM sodium orthovanadate, and 20 mM ATP for 20 min at 30 C. Reactions were terminated by adding SDS-PAGE sample buffer and boiling at 100 C for 5 min. Proteins were resolved by SDS-PAGE and transferred onto nitrocellulose membranes for exposure to X-ray film.
Analysis of PTEN and Rak Expression in Breast Cancer Samples
The proteins in 42 breast cancer tissue samples obtained from the institutional breast cancer bank were extracted by RIPA buffer and analyzed for expression of Rak and PTEN. After western blotting analysis, the intensity of Rak and PTEN bands was quantitated, and the relationships between Rak and PTEN protein expression were analyzed by linear regression. p < 0.05 was considered significant. This study was performed according to protocols approved by the M.D. Anderson Cancer Center Institutional Review Board, and all subjects provided written informed consent.
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